Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback